GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cellyan Biotechnology Co HKPD · USD

Industrials · US listing · 🇺🇸 United States

Compare

1.53

+5.17%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

$13.4m

FY2023FY2026

Net income

−$1.1m

FY2023FY2026

Free cash flow

−$787,072

FY2023FY2026

Shareholders' equity

$9.6m

FY2023FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023
Revenue$13.4m$20.3m$16.7m$12.6m
Gross profit$1.4m$2.4m$3.6m$2.7m
Operating income−$994,902$133,779$1.6m$1.0m
Net income−$1.1m−$27,056$1.3m$998,196
Diluted earnings per share-0.03-0.000.130.15

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023
Total assets$12.8m$9.4m$8.7m$3.4m
Cash and short-term investments$221,841$3.0m$619,575$524,613
Total liabilities$3.3m$4.4m$4.4m$2.8m
Debt$1.3m$2.4m$2.1m$691,076
Shareholders' equity$9.6m$5.0m$4.3m$585,242
Shares outstanding36m11m10m7m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023
Cash from operations−$751,602$569,214−$394,330$1.7m
Capital spending−$35,470−$154,988−$88,018−$117,705
Free cash flow−$787,072$414,226−$482,348$1.6m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024
Revenue$6.3m$7.1m$4.6m$9.2m$4.6m$11.1m$5.5m$9.7m
Gross profit$455,545$930,764$254,778$509,556$254,778$1.9m$952,802$2.2m
Operating income−$1.2m$234,319−$447,500−$895,000−$447,500$1.0m$513,518$1.3m
Net income−$1.3m$153,735−$427,808−$855,616−$427,808$828,560$414,280$1.1m
Diluted earnings per share-0.040.01-0.04-0.08-0.040.080.040.10
Total assets$12.8m$9.6m$9.4m$9.4m$9.4m$10.2m$10.2m$8.7m
Cash and short-term investments$221,841$2.5m$3.0m$3.0m$3.0m$364,990$364,990$619,575
Debt$1.2m$808,406$864,661$2.4m$864,661$2.1m$1.1m$2.0m
Shareholders' equity$9.6m$5.1m$5.0m$5.0m$5.0m$5.4m$5.4m$4.3m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue2.0%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin11.3%16.0%——

Valuation history

At each fiscal year end

FY2026FY2025
Price to earnings-58.6-3660.4
Price to sales5.04.9

Share price return

Finished calendar years

2025
Return-75%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 20-to-1 reverse split · 26 Oct 2026

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.